Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // August 10th, 2011 // 6:56 am
Good morning, everyone. Yet another shiny day is unfolding here on the Pharmalot corporate campus, where the crickets are chirping, the mascots are fertilizing the weeds and the shortest of short people is slumbering. As usual, we are brewing a cup of stimulation to speed things along. We trust you can relate. So please join us. Meanwhile, here are some tidibits from around the world. As the editor notes, check back for additions. Have a great day and hope you accomplish much…
Glass Lewis Backs One Icahn Nominee To Forest Board (Reuters)
Ranbaxy Labs Closes Plant In The US (The Economic Times)
Roche’s Herceptin Has Higher Heart Risk For Older Women (Bloomberg News)
Lundbeck Cuts R&D Jobs, But Adds Sales Reps (Reuters)
Glaxo Wants OK To Market Horizant For Shingles Pain (MedCity News)
Biogen And Abbott Say MS Drug Met Main Study Goal (Associated Press)
Ironwood Seeks FDA Approval For Its First Drug (The Boston Globe)
Pfizer Is Moving Fast Toward Real-Time Release (InPharma Technologist)
EDITOR’S NOTE: Please check this post for updates throughout the morning
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Abbott Laboratories, Biogen, Carl Icahn, FDA, Forest Laboratories, Glass Lewis, GlaxoSmithKline, Herceptin, Horizant, Ironwood Pharmaceuticals, jobs, Lundbeck, MS, Multiple Sclerosis, Pfizer, Ranbaxy Laboratories, RD, Real Time Release, Restless Legs Syndrome, Roche, RTR, Sales Reps, Shingles